EE05305B1 - Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend - Google Patents

Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend

Info

Publication number
EE05305B1
EE05305B1 EEP200200283A EEP200200283A EE05305B1 EE 05305 B1 EE05305 B1 EE 05305B1 EE P200200283 A EEP200200283 A EE P200200283A EE P200200283 A EEP200200283 A EE P200200283A EE 05305 B1 EE05305 B1 EE 05305B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical formulation
intranasal administration
preparation
zolmitriptan
formulation containing
Prior art date
Application number
EEP200200283A
Other languages
English (en)
Estonian (et)
Inventor
Roy Dearn Alan
Louise Williamson Sarah
John Summers Simon
John Coomber Trevor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05305(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200283A publication Critical patent/EE200200283A/xx
Publication of EE05305B1 publication Critical patent/EE05305B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EEP200200283A 1999-12-03 2000-11-28 Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend EE05305B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (2)

Publication Number Publication Date
EE200200283A EE200200283A (et) 2003-06-16
EE05305B1 true EE05305B1 (et) 2010-06-15

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200283A EE05305B1 (et) 1999-12-03 2000-11-28 Zolmitriptaani sisaldav ravimpreparaat, meetod selle valmistamiseks ning seda sisaldav intranasaalse manustamise vahend

Country Status (28)

Country Link
US (2) US6750237B1 (cs)
EP (1) EP1237551B1 (cs)
JP (1) JP2003515559A (cs)
KR (1) KR100670092B1 (cs)
CN (1) CN1222287C (cs)
AT (1) ATE291914T1 (cs)
AU (1) AU778092B2 (cs)
BR (1) BRPI0016138B8 (cs)
CA (1) CA2392050C (cs)
CZ (1) CZ301528B6 (cs)
DE (1) DE60019162T2 (cs)
EE (1) EE05305B1 (cs)
ES (1) ES2236001T3 (cs)
GB (2) GB9928578D0 (cs)
HK (2) HK1048442B (cs)
HU (1) HU229458B1 (cs)
IL (2) IL149578A0 (cs)
IS (1) IS2135B (cs)
MX (1) MXPA02005319A (cs)
NO (1) NO322119B1 (cs)
NZ (1) NZ518862A (cs)
PL (1) PL200679B1 (cs)
PT (1) PT1237551E (cs)
RU (1) RU2255736C2 (cs)
SK (1) SK287228B6 (cs)
UA (1) UA75059C2 (cs)
WO (1) WO2001039772A1 (cs)
ZA (1) ZA200203704B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
EP1744784A2 (en) * 2004-05-11 2007-01-24 Becton, Dickinson and Company Formulations of anti-pain agents and methods of using the same
ES2624585T3 (es) * 2004-05-28 2017-07-17 Imaginot Pty Ltd. Sistema de suministro de compuesto terapéutico oral
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
CA2629904C (en) * 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
BRPI0715579A2 (pt) * 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
KR101825972B1 (ko) 2010-10-15 2018-02-06 콘테라 파르마 에이피에스 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
PT2838517T (pt) 2012-04-18 2018-01-04 Contera Pharma Aps Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
CA3030089C (en) 2016-07-11 2024-04-23 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100215627B1 (ko) * 1990-06-07 1999-08-16 레슬리 제인 에드워즈 치료용 헤테로사이클 화합물
GB9012672D0 (en) * 1990-06-07 1990-08-01 Wellcome Found Therapeutic heterocyclic compounds
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
CA2259418A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
GB2373726B (en) 2004-10-20
CA2392050A1 (en) 2001-06-07
ZA200203704B (en) 2003-10-29
KR20020058051A (ko) 2002-07-12
KR100670092B1 (ko) 2007-01-17
IL149578A0 (en) 2002-11-10
GB2373726A (en) 2002-10-02
UA75059C2 (uk) 2006-03-15
NO322119B1 (no) 2006-08-14
HK1048442B (zh) 2005-05-13
HU229458B1 (en) 2013-12-30
SK7532002A3 (en) 2002-12-03
EP1237551A1 (en) 2002-09-11
CN1402636A (zh) 2003-03-12
DE60019162T2 (de) 2006-02-02
PL200679B1 (pl) 2009-01-30
RU2255736C2 (ru) 2005-07-10
GB9928578D0 (en) 2000-02-02
US7220767B2 (en) 2007-05-22
GB0214845D0 (en) 2002-08-07
BRPI0016138B8 (pt) 2021-05-25
BR0016138A (pt) 2002-08-06
PL357597A1 (en) 2004-07-26
CA2392050C (en) 2009-11-24
RU2002117649A (ru) 2004-01-27
BR0016138B1 (pt) 2013-09-10
JP2003515559A (ja) 2003-05-07
ATE291914T1 (de) 2005-04-15
HUP0203597A3 (en) 2005-07-28
SK287228B6 (sk) 2010-03-08
NO20022525L (no) 2002-05-28
HK1048445B (en) 2005-08-26
ES2236001T3 (es) 2005-07-16
NO20022525D0 (no) 2002-05-28
CZ20021901A3 (cs) 2002-11-13
EP1237551B1 (en) 2005-03-30
HK1048442A1 (en) 2003-04-04
DE60019162D1 (de) 2005-05-04
WO2001039772A1 (en) 2001-06-07
CN1222287C (zh) 2005-10-12
EE200200283A (et) 2003-06-16
HK1048445A1 (en) 2003-04-04
HK1053430A1 (en) 2003-10-24
AU1715701A (en) 2001-06-12
MXPA02005319A (es) 2002-12-06
HUP0203597A2 (hu) 2003-02-28
US6750237B1 (en) 2004-06-15
NZ518862A (en) 2004-02-27
AU778092B2 (en) 2004-11-18
IL149578A (en) 2008-04-13
PT1237551E (pt) 2005-07-29
CZ301528B6 (cs) 2010-04-07
IS6394A (is) 2002-05-24
IS2135B (is) 2006-08-15
US20040214899A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
NO20022525D0 (no) Farmasöytiske formuleringer inneholdende zolmitriptan
TW200500083A (en) Formulation of human antibodies for treating tnf-α associated disorders
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
SG128415A1 (en) Device for liquid treatment of wafer-shaped articles
SE0100901D0 (sv) New composition
EP1129089A4 (en) SPIRO-INDOLE AS Y5 RECEPTOR ANTAGONISTS
NO20011440D0 (no) mGluR5-antagonister for behandling av smerte og angst
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
NO20004419L (no) Ny anvendelse
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
SE0202365D0 (sv) New formulation and use thereof
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
SE0002353D0 (sv) New use
ES2138937B1 (es) Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
DE60004819D1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
AU2003301174A8 (en) Liposomal analgesic formulation and use
UA49675A (uk) Спосіб лікування орнітозної пневмонії

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231